|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions显示文摘AIM To investigate daclatasvir(DCV) and asunaprevir(ASV) efficacy in hepatitis C(HCV) patients, with respect to resistance-associated substitutions(RASs).METHODS A total of 392 HCV-infected patients from multiple centers were included in this study. We evaluated their clinical courses and sustained virologic responses(SVR) according to pretreatment factors(gender, age, history of interferon-based regimens, platelet counts, level of viremia, pretreatment NA5A:L31, and Y93 substitutions). We also analyzed the pretreatment and post-treatment major RASs of NS3:D168, NS5A:L31 and Y93 substitutions using a direct-sequencing method in 17 patients who were unable to achieve SVR at 12 wk after treatment completion(SVR12).RESULTS The overall SVR12 rate was 88.3%. Thirty-one patients discontinued treatment before 24 wk because of adverse events, 23 of whom achieved SVR12. There were no significant differences in SVR12 rates with respect to gender, age, history of interferon-based regimens, and platelet counts. The SVR12 rate in patients with viral loads of ≥ 6.0 log IU/m L was significantly lower than those with viral loads of < 6.0 log IU/m L(P < 0.001). The SVR12 rate in patients with Y93 substitution-positive was significantly lower than those with Y93 substitution-negative(P < 0.001). The L31 substitution-positive group showed a lower SVR12 rate than the L31 substitution-negative group, but the difference was not statistically significant. Seventeen patients who did not achieve SVR12 and had available pretreatment and post-treatment sera had additional RASs in NS3:D168, NS5:L31, and Y93 substitution at treatment failure.CONCLUSION Combination of DCV and ASV is associated with a high SVR rate. Baseline RASs should be thoroughly assessed to avoid additional RASs after treatment failure. | Hideki Fujii Atsushi Umemura Taichiro Nishikawa Kanji Yamaguchi Michihisa Moriguchi Hideki Nakamura Kohichiroh Yasui Masahito Minami Saiyu Tanaka Hiroki Ishikawa Hiroyuki Kimura Shiro Takami Yasuyuki Nagao Toshihide Shima Yoshito Itoh | 2017 | World Journal of Hepatology2017，9，25： | 3 |
| 2 | Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma显示文摘 | Kohichiroh Yasui Etsuko Hashimoto Yasuji Komorizono Kazuhiko Koike Shigeki Arii Yasuharu Imai Toshihide Shima Yoshihiro Kanbara Toshiji Saibara Takahiro Mori Sumio Kawata Hirofumi Uto Shiro Takami Yoshio Sumida Toshinari Takamura Miwa Kawanaka Takeshi Oka | 2011 | Clinical Gastroenterology and Hepatology2011，，5： | 2 |
| 3 | Effects of ice-seeding temperature and intraeellular trehalose contents on survival of frozen Saccharomyces cerevisiae cells 显示文摘 | Toshihide Nakamura Hiroshi Takagi Jun Shima | 2009 | Cryobiology2009，58，2： | 1 |
| 4 | Functional genomic analysis of commercial baker' s yeast during initial stages of model dough - fermentation 显示文摘 | Fumiko Tanaka Akira Ando Toshihide Nakamura Hiroshi Takagi and Jun Shima | 2006 | Food Microbiology2006，23，8： | 1 |
| 5 | Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching显示文摘AIM: To compare efficacy of telaprevir(TVR) and simeprevir(SMV) combined with pegylated interferon(PEG-IFN) and ribavirin(RBV) while treating chronic hepatitis C(CHC). METHODS: In all, 306 CHC patients were included in this study. There were 159 patients in the TVR combination therapy group and 147 patients in the SMV combination therapy group. To evaluate pretreatment factors contributing to sustained virological response at 12 wk(SVR12), univariate and multivariate analyses were performed in TVR and SMV groups. To adjust for patient background between TVR and SMV groups, propensity score matching was performed. Virological response during treatment and SVR12 were evaluated.RESULTS: Overall rates of SVR12 [undetectable serum hepatitis C virus(HCV) RNA levels] were 79.2% and 69.4% in TVR and SMV groups, respectively. Patients in the SMV group were older, had higher serum HCV RNA levels, lower hemoglobin, higher prevalence of unfavorable interleukin-28B(IL28B) genotype(rs8099917), and poorer response to previous PEG-IFN and RBV treatment. Propensity score matching was performed to adjust for backgrounds(n = 104) and demonstrated SVR12 rates of 74.0% and 73.1% in the TVR and SMV groups, respectively. In the TVR group, discontinuation rates were higher because of adverse events; however, breakthrough and nonresponse was more frequent in the in SMV group. Multivariate analysis revealed IL28 B genotype(rs8099917) as the only independent predictive factor of SVR12 in both groups.CONCLUSION: SVR12 rates were almost identical following propensity score matching. | Hideki Fujii Takeshi Nishimura Atsushi Umemura Taichiro Nishikawa Kanji Yamaguchi Michihisa Moriguchi Yoshio Sumida Hironori Mitsuyoshi Chihiro Yokomizo Saiyu Tanaka Hiroki Ishikawa Kenichi Nishioji Hiroyuki Kimura Shiro Takami Yasuyuki Nagao Takayuki Takeuchi Toshihide Shima Yoshihiko Sawa Masahito Minami Kohichiroh Yasui Yoshito Itoh | 2015 | World Journal of Hepatology2015，7，28： | 1 |
| 6 | Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma显示文摘 | Kohichiroh Yasui Etsuko Hashimoto Yasuji Komorizono Kazuhiko Koike Shigeki Arii Yasuharu Imai Toshihide Shima Yoshihiro Kanbara Toshiji Saibara Takahiro Mori Sumio Kawata Hirofumi Uto Shiro Takami Yoshio Sumida Toshinari Takamura Miwa Kawanaka Takeshi Oka | 2011 | Clinical Gastroenterology and Hepatology2011，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员